AIIMS原发性IgA肾病队列(APPROACH):肾素-血管紧张素阻断的支持治疗
该前瞻性研究纳入96例未治疗的IgA肾病患者,接受ACEi/ARB及血压控制治疗6个月,3个月和6个月蛋白尿缓解率分别为36.5%和55.2%,完全缓解率分别为6.3%和31.3%。基线eGFR低、血白蛋白低、无症状高尿酸血症及病理E1/T1/T2病变者缓解率更低,17.7%患者因不耐受停药。
要点
- ACEi/ARB支持治疗6个月可使过半IgA肾病患者蛋白尿缓解。
- 延长治疗至6个月可提高缓解率,完全缓解率从6.3%升至31.3%。
- 基线肾功能差、低白蛋白血症及病理活动/慢性病变者应答和耐受性较差。
核心结论
- 精细的支持治疗并优化ACEi/ARB剂量可使半数IgA肾病患者在6个月内达到蛋白尿缓解。
- 延长治疗至6个月可提高缓解率,但严重临床和病理病变者耐受性和应答较差。
研究设计与样本
- 前瞻性研究,纳入96例未治疗的IgA肾病患者,尿蛋白≥1 g/d且eGFR≥30 ml/min/1.73 m2。
- 治疗包括ACEi(雷米普利)或ARB(氯沙坦,用于ACEi不耐受者),血压控制至≤130/80 mm Hg,随访6个月。
- 主要结局为蛋白尿缓解,完全缓解定义为尿蛋白<0.5 g/d,部分缓解定义为尿蛋白<1 g/d且较基线下降≥50%且eGFR下降≤25%。
主要发现
- 3个月时36.5%患者达到缓解(完全缓解6.3%),6个月时55.2%达到缓解(完全缓解31.3%)。
- 未缓解者基线eGFR较低(P=0.002)、血清白蛋白较低(P<0.001)、无症状高尿酸血症(P<0.001)、尿蛋白较高(P=0.076)。
- 未缓解者病理E1病变(P=0.053)和T1/T2病变(P=0.009)更常见。
- 17例(17.7%)患者需停用ACEi/ARB,这些患者年龄较大(P=0.085)、eGFR较低(P<0.002)、血清白蛋白较低(P=0.001)、E1病变(P=0.012)和T1/T2病变(P=0.001)更多。
关键数值与推荐
- 完全缓解:尿蛋白<0.5 g/d;部分缓解:尿蛋白<1 g/d且较基线下降≥50%,且eGFR下降≤25%。
- 血压控制目标:≤130/80 mm Hg。
- 71.9%患者接受≥75%最大批准剂量的ACEi/ARB。
临床怎么用
- 对IgA肾病患者应优化ACEi/ARB剂量并控制血压≤130/80 mm Hg,治疗至少6个月以评估疗效。
- 基线肾功能差、低白蛋白血症、高尿酸血症及病理E1/T1/T2病变者应答和耐受性可能较差,需密切监测。
局限性
- 单中心前瞻性研究,样本量96例,随访仅6个月。
- 未报告安慰剂对照或非支持治疗对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Renin-angiotensin system (RAS) blockade using angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) is first-line therapy for IgA nephropathy (IgAN). There is a paucity of information on the predictors and magnitude of response to this treatment. METHODS: In a prospective study, treatment-naive patients with IgAN with urinary protein ≥ 1 g/d and estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m2 received supportive treatment including ACEi (ramipril) or ARB (losartan) in patients intolerant to ACEi, and optimal blood pressure (BP) control to ≤130/80 mm Hg, with a follow-up of 6 months. The primary outcome was remission of proteinuria. Complete remission (CR) was defined as proteinuria < 0.5 g/d and partial remission (PR) as proteinuria < 1g/d with at least a 50% decline from the baseline with stable renal function (≤ 25% reduction in eGFR). RESULTS: A total of 96 patients were analyzed, with a mean age of 33.3 ± 10.2 years, baseline eGFR 74.0 ± 30.9 ml/min per 1.73 m2, and urinary protein 2.6 ± 1.2 g/d. In all, 71.9% patients received ≥ 75% of the maximum approved dose of ACEi/ARB. Remission was observed in 36.5% (CR, 6.3%) patients at 3 months and in 55.2% (CR, 31.3%) at 6 months. Patients who failed to achieve remission had lower baseline eGFR (P = 0.002) and serum albumin levels (P< 0.001), asymptomatic hyperuricemia (P < 0.001), and higher proteinuria (P = 0.076). E1 (P= 0.053) and T1/T2 (P = 0.009) lesions were more frequent on histology. The ACEi/ARB had to be discontinued in 17 (17.7%) patients. These patients were older (P= 0.085) with lower eGFR (P < 0.002) and serum albumin levels (P = 0.001) and more E1 (P = 0.012) and T1/T2 (P = 0.001) lesions on histology. CONCLUSION: Meticulous supportive therapy with optimal use of ACEi/ARB achieved remission in half of IgAN patients in this study. Increasing the treatment duration to 6 months improved remission rates. Patients with severe clinical and histological disease were less likely to tolerate and respond to treatment with RAS blockade.
引用
- Bagchi S, Mani K, Swamy A, et al. Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study. Kidney Int Rep. 2021. PMID: 34169207. doi:10.1016/j.ekir.2021.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。